benzazepines

Summary

Summary: Compounds with BENZENE fused to AZEPINES.

Top Publications

  1. doi Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
    Nancy A Rigotti
    General Medicine Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Tobacco Research and Treatment Center, Boston, Mass 02114, USA
    Circulation 121:221-9. 2010
  2. ncbi The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial
    Raymond Niaura
    Brown University, Providence, RI, USA
    Curr Med Res Opin 24:1931-41. 2008
  3. doi Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
  4. pmc Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
    Sonal Singh
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    CMAJ 183:1359-66. 2011
  5. doi Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial
    Donald P Tashkin
    Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1690, USA
    Chest 139:591-9. 2011
  6. doi Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties
    Leopoldo Luistro
    Discovery Oncology, Discovery Chemistry, In Silico Sciences, Non Clinical Safety, Drug Metabolism, and RNA Therapeutics, Hoffmann La Roche, Inc, Nutley, New Jersey, USA
    Cancer Res 69:7672-80. 2009
  7. doi Varenicline for smoking cessation: a placebo-controlled, randomized study
    Chen Wang
    Department of Epidemiology, Beijing Institute of Respiratory Medicine, WHO Collaborating Center for Tobacco or Health, Beijing Chao Yang Hospital Affiliated, Capital Medical University, Beijing, China
    Respirology 14:384-92. 2009
  8. pmc Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
    Pia Steensland
    Ernest Gallo Clinic and Research Center, University of California, San Francisco, 5858 Horton Street, Suite 200, Emeryville, CA 94608, USA
    Proc Natl Acad Sci U S A 104:12518-23. 2007
  9. doi Pharmacogenetics of smoking cessation therapy
    Gustavo L Kortmann
    Departamento de Genetica, Instituto de Biociencias, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
    Am J Med Genet B Neuropsychiatr Genet 153:17-28. 2010
  10. doi Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand
    Drug Saf 35:33-43. 2012

Detail Information

Publications274 found, 100 shown here

  1. doi Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial
    Nancy A Rigotti
    General Medicine Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Tobacco Research and Treatment Center, Boston, Mass 02114, USA
    Circulation 121:221-9. 2010
    ..Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown...
  2. ncbi The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial
    Raymond Niaura
    Brown University, Providence, RI, USA
    Curr Med Res Opin 24:1931-41. 2008
    ..To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation...
  3. doi Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
    ..Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in heart failure...
  4. pmc Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
    Sonal Singh
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    CMAJ 183:1359-66. 2011
    ..We conducted a systematic review and meta-analysis of randomized controlled trials to ascertain the serious adverse cardiovascular effects of varenicline compared with placebo among tobacco users...
  5. doi Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial
    Donald P Tashkin
    Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 1690, USA
    Chest 139:591-9. 2011
    ..To our knowledge, this is the first randomized clinical trial to compare the efficacy and safety of varenicline tartrate vs placebo in smokers with mild to moderate COPD...
  6. doi Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties
    Leopoldo Luistro
    Discovery Oncology, Discovery Chemistry, In Silico Sciences, Non Clinical Safety, Drug Metabolism, and RNA Therapeutics, Hoffmann La Roche, Inc, Nutley, New Jersey, USA
    Cancer Res 69:7672-80. 2009
    ..These preclinical results support evaluation of RO4929097 in clinical studies using an intermittent dosing schedule. A multicenter phase I dose escalation study in oncology is under way...
  7. doi Varenicline for smoking cessation: a placebo-controlled, randomized study
    Chen Wang
    Department of Epidemiology, Beijing Institute of Respiratory Medicine, WHO Collaborating Center for Tobacco or Health, Beijing Chao Yang Hospital Affiliated, Capital Medical University, Beijing, China
    Respirology 14:384-92. 2009
    ..This study evaluated the efficacy of a standard regimen of varenicline compared with placebo for smoking cessation in 333 subjects in China, Singapore and Thailand...
  8. pmc Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
    Pia Steensland
    Ernest Gallo Clinic and Research Center, University of California, San Francisco, 5858 Horton Street, Suite 200, Emeryville, CA 94608, USA
    Proc Natl Acad Sci U S A 104:12518-23. 2007
    ..The selectivity of varenicline in decreasing ethanol consumption combined with its reported safety profile and mild side effects in humans suggest that varenicline may prove to be a treatment for alcohol dependence...
  9. doi Pharmacogenetics of smoking cessation therapy
    Gustavo L Kortmann
    Departamento de Genetica, Instituto de Biociencias, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
    Am J Med Genet B Neuropsychiatr Genet 153:17-28. 2010
    ..However, the current scientific evidence still does not support the use of pharmacogenetic tests in routine smoking cessation therapy...
  10. doi Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand
    Drug Saf 35:33-43. 2012
    ..Cases of cardiovascular events, including myocardial infarction (MI) and cardiac dysrhythmias, have been noted from spontaneous reporting systems...
  11. doi A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo
    Dahlia Garza
    Pfizer Pharmaceuticals Inc, New York, New York 10017, USA
    Biol Psychiatry 69:1075-82. 2011
    ..There have been spontaneous postmarketing reports of neuropsychiatric adverse events (NPAEs) in smokers without a history of psychiatric illness quitting with varenicline...
  12. doi Highly cytotoxic copper(II) complexes with modified paullone ligands
    Michael F Primik
    Institute of Inorganic Chemistry, University of Vienna, Austria
    Inorg Chem 49:302-11. 2010
    ..All of the compounds evaluated are cytotoxic, with complexes 3 and 4 exhibiting IC(50) values in the nanomolar range...
  13. pmc Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
    Mark J Eisenberg
    Division of Cardiology and Clinical Epidemiology, Sir Mortimer B Davis Jewish General Hospital and McGill University, McGill University, Montreal, QC
    CMAJ 179:135-44. 2008
    ..However, few direct or indirect comparisons of such interventions have been conducted. We performed a meta-analysis to compare the treatment effects of 7 approved pharmacologic interventions for smoking cessation...
  14. ncbi Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure
    Paul Mulder
    INSERM U644, UFR de Medecine et de Pharmacie, Rouen, France
    Circulation 109:1674-9. 2004
    ..However, the long-term effects of HRR on cardiac function and remodeling are unknown...
  15. pmc Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling
    Gerard J O'Sullivan
    Molecular and Cellular Therapeutics and RCSI Research Institute, Royal College of Surgeons in Ireland, Dublin 2, Ireland
    Neuropharmacology 54:1051-61. 2008
    ..These findings indicate that D(1), and to a lesser extent D(5), receptor coupling to DARPP-32, ERK1/2 and glutamatergic signalling is involved in mediating the convulsant effects of SKF 83822...
  16. pmc Varenicline reduces alcohol self-administration in heavy-drinking smokers
    Sherry A McKee
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA
    Biol Psychiatry 66:185-90. 2009
    ..Varenicline, a partial nicotinic agonist with high affinity for the alpha4beta2 nAChR receptor, reduced ethanol intake in rodents. We aimed to test whether varenicline would reduce alcohol consumption and alcohol craving in humans...
  17. pmc Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells
    Altaf A Dar
    Departments of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer Res 68:8998-9004. 2008
    ..Taken together, our results indicate that AURKA regulates TAp73-dependent apoptosis and highlight the potential of the AURKA inhibitor MLN8054 in treating cancers that are defective in p53 signaling...
  18. doi Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis
    Serena Tonstad
    Department of Preventive Cardiology, Oslo University Hospital Ulleval, Oslo, Norway
    Drug Saf 33:289-301. 2010
    ..In postmarketing surveillance, neuropsychiatric symptoms have appeared; however, their incidence and causal relationship to varenicline is not known...
  19. doi Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women
    Steven R Smith
    Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA
    Obesity (Silver Spring) 17:494-503. 2009
    ..Lorcaserin was well tolerated and efficacious for weight reduction in this 12-week study. Longer-term trials employing behavior modification will be needed to more fully assess its safety and efficacy...
  20. pmc Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum
    Subramaniam Jayanthi
    Molecular Neuropsychiatry Research Branch, National Institute of Drug Abuse, National Institutes of Health NIH Department of Health and Human Services DHHS, Intramural Research Program, Baltimore, MD, USA
    PLoS ONE 4:e6092. 2009
    ..Our data also suggest that METH-induced toxicity might be a useful model to dissect molecular mechanisms involved in ER stress-dependent events in the rodent brain...
  21. doi MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo
    Jessica J Huck
    Millennium Pharmaceuticals, Cambridge, MA 02139, USA
    Mol Cancer Res 8:373-84. 2010
    ..Taken together, this data shows that senescence is a terminal outcome of Aurora A inhibition and supports the evaluation of senescence biomarkers in clinic samples...
  22. doi I(f) inhibition in cardiovascular diseases
    Catherine Thollon
    Cardiovascular Department, Institut de Recherches Servier, Suresnes, France
    Adv Pharmacol 59:53-92. 2010
    ....
  23. pmc Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
    Judith J Prochaska
    Department of Psychiatry and Center for Tobacco Control Research and Education, University of California, San Francisco, CA 94143 0984, USA
    BMJ 344:e2856. 2012
    ..To examine the risk of treatment emergent, cardiovascular serious adverse events associated with varenicline use for tobacco cessation...
  24. doi Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
    Kim Fox
    Royal Brompton Hospital, London, UK
    Lancet 372:807-16. 2008
    ..We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction...
  25. pmc Behavioral counseling and varenicline treatment for smoking cessation
    Gary E Swan
    SRI International, Menlo Park, California 94025, USA
    Am J Prev Med 38:482-90. 2010
    ..Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence...
  26. doi Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline
    Michael B Steinberg
    Division of General Internal Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 125 Paterson Street, Suite 2304, New Brunswick, NJ 08903, USA
    Addict Behav 36:1127-32. 2011
    ..This is the first randomized, double-blinded, placebo-controlled pilot trial utilizing varenicline and post-discharge, in-person behavioral treatment for hospitalized smokers...
  27. pmc The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study
    James Poling
    Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, Connecticut 06516, USA
    Am J Addict 19:401-8. 2010
    ..These preliminary findings may point to potential therapeutic value of varenicline for smoking cessation in cocaine users maintained on methadone...
  28. pmc Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor
    S C R Lummis
    Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, United Kingdom
    J Pharmacol Exp Ther 339:125-31. 2011
    ..Therefore, activation of human 5-HT(3) receptors may be responsible for some of the side effects that preclude use of higher doses during varenicline treatment...
  29. doi Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study
    Fanny Vaillant
    Laboratory of Medical Pharmacology, INSERM ERI 22, Grange Blanche Medical School, Claude Bernard University, Lyon, France
    J Cardiovasc Pharmacol 52:548-54. 2008
    ..Tachycardia often facilitates ischemic ventricular fibrillation (VF)...
  30. doi Specific inhibition of HCN channels slows rhythm differently in atria, ventricle and outflow tract and stabilizes conduction in the anoxic-reoxygenated embryonic heart model
    Alexandre Sarre
    Department of Physiology, Faculty of Biology and Medicine, 7 rue du Bugnon, CH 1005 Lausanne, Switzerland
    Pharmacol Res 61:85-91. 2010
    ..Thus, HCN channels are specifically distributed and control finely atrial, ventricular and outflow tract pacemakers as well as conduction in the embryonic heart under normoxia and throughout anoxia-reoxygenation...
  31. ncbi The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease
    J P Vilaine
    Institut de Recherches Servier, Division Pathologies Cardiaques et Vasculaires, 11 rue des Moulineaux, 92150 Suresnes, France
    Pharmacol Res 53:424-34. 2006
    ....
  32. pmc Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats
    Susmita Chatterjee
    Ernest Gallo Clinic and Research Center, University of California San Francisco, Emeryville, CA 94608, USA
    Neuropsychopharmacology 36:603-15. 2011
    ..CP-601932 has been shown to be safe in humans and may represent a potential novel treatment for AUDs...
  33. ncbi Opposing roles of D1 and D2 receptors in appetitive conditioning
    Yaniv S Eyny
    Department of Psychology and Program in Neurobiology and Behavior, Columbia University, New York, New York 10027, USA
    J Neurosci 23:1584-7. 2003
    ....
  34. pmc A preliminary investigation of varenicline for heavy drinking smokers
    Lisa M Fucito
    Department of Psychiatry, CMHC S200, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
    Psychopharmacology (Berl) 215:655-63. 2011
    ..However, varenicline has not been tested in heavy drinkers, and it remains to be determined whether varenicline could reduce alcohol craving and consumption in smokers who are trying to quit smoking...
  35. doi Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London, UK
    Eur Heart J 30:2337-45. 2009
    ..We performed a post hoc analysis of the effect of ivabradine in BEAUTIFUL patients whose limiting symptom at baseline was angina, particularly in terms of coronary outcomes...
  36. pmc Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction
    G Heusch
    Institute for Pathophysiology, University of Essen Medical School, Essen, Germany
    Br J Pharmacol 155:970-1. 2008
    ..The heart rate dependency of ivabradine's benefit for atherosclerotic vascular function is contradictory, and that on post-infarct remodelling is entirely unclear...
  37. doi Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice
    Florian Custodis
    Klinik fur Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitatsklinikum des Saarlandes, 66424 Homburg Saar, Germany
    Circulation 117:2377-87. 2008
    ..We hypothesized that selective heart rate reduction may influence endothelial function and atherogenesis and tested the effects of the I(f) current inhibitor ivabradine in apolipoprotein E-deficient mice...
  38. ncbi An update on therapeutics for tobacco dependence
    Tim Lancaster
    University of Oxford, Cochrane Tobacco Addiction Review Group, Department of Primary Healthcare, Old Road, Headington, Oxford, OX3 7LF, UK
    Expert Opin Pharmacother 9:15-22. 2008
    ..Recent evidence suggests that the nicotine-receptor partial agonist varenicline is at least as effective as nicotine replacement therapy and antidepressants...
  39. pmc Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
    Karl Fagerström
    Smokers Information Centre, Fagerstrom Consulting AB, Berga Alle 1, 25452 Helsingborg, Sweden
    BMJ 341:c6549. 2010
    ..To assess the efficacy and safety of varenicline (a licensed cigarette smoking cessation aid) in helping users of smokeless tobacco to quit...
  40. ncbi Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen
    Eduard I Dedkov
    Department of Biomedical Sciences, New York College of Osteopathic Medicine NYIT, Old Westbury, NY 11568, USA
    Am J Physiol Heart Circ Physiol 293:H590-8. 2007
    ..Therefore, our data reveal that improved maximal myocardial perfusion and coronary reserve in MI + IVA rats are most likely the result of reduced periarteriolar collagen rather than enhanced arteriolar growth...
  41. doi Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling
    Claudio Ceconi
    Department of Cardiology, University of Ferrara, Ferrara, Italy
    Am J Physiol Heart Circ Physiol 300:H366-73. 2011
    ..05). The HR-reducing properties of ivabradine prevent changes in the global phenotype of LV remodeling in the rat, optimize energy consumption, and avoid electrophysiological and structural remodeling...
  42. ncbi Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy
    Wolfgang F Schmid
    Institute of Inorganic Chemistry, University of Vienna, Wahringerstr 42, A 1090 Vienna, Austria
    J Med Chem 50:6343-55. 2007
    ..3)H-Thymidine incorporation assays revealed the compounds to lower the rate of DNA synthesis, and flow cytometric analyses showed cell cycle arrest mainly in G 0/ G 1 phase...
  43. pmc Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy
    Lukas K Filak
    Institute of Inorganic Chemistry, University of Vienna, Wahringer Strasse 42, 1090, Vienna, Austria
    J Biol Inorg Chem 15:903-18. 2010
    ..L ( 1 )) and N'-(11H-indolo[3,2-c]quinolin-6-yl)-N,N-dimethylethane-1,2-diamine (L ( 2 )) and indolo[3,2-d]benzazepines N-(7,12-dihydroindolo-[3,2-d][1]benzazepin-6-yl)-ethane-1,2-diamine (L ( 3 )) and N'-(7,12-dihydroindolo-[3,2-d]..
  44. pmc Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database
    D Gunnell
    University of Bristol, Department of Social Medicine, University of Bristol, Bristol BS8 2PS
    BMJ 339:b3805. 2009
    ..To determine whether varenicline, a recently licensed smoking cessation product, is associated with an increased risk of suicide and suicidal behaviour compared with alternative treatments bupropion and nicotine replacement therapy...
  45. doi Multicenter, placebo-controlled trial of lorcaserin for weight management
    Steven R Smith
    Translational Research Institute for Metabolism and Diabetes, Florida Hospital and the Sanford Burnham Institute, Winter Park, FL 32789, USA
    N Engl J Med 363:245-56. 2010
    ..Lorcaserin is a selective serotonin 2C receptor agonist that could be useful in reducing body weight...
  46. pmc Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
    Neal L Benowitz
    Department of Medicine, Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, University of California, San Francisco, California 94143 1220, USA
    Annu Rev Pharmacol Toxicol 49:57-71. 2009
    ..Pharmacotherapeutic approaches to tobacco addiction include nicotine replacement, bupropion, and varenicline, the latter a selective nicotine receptor partial agonist...
  47. ncbi Therapeutic potential of vasopressin receptor antagonists
    Farhan Ali
    Heart Failure Program, Wayne State University, Detroit, Michigan, USA
    Drugs 67:847-58. 2007
    ..Ongoing clinical trials should further define the scope of the potential therapeutic role of VRAs...
  48. ncbi Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
    David Gonzales
    Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 296:47-55. 2006
    ..The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation...
  49. ncbi Heterosynaptic co-activation of glutamatergic and dopaminergic afferents is required to induce persistent long-term potentiation
    Colin M O'Carroll
    Department of Neuroscience, 1, George Square, University of Edinburgh, Edinburgh EH8 9JZ, UK
    Neuropharmacology 47:324-32. 2004
    ....
  50. ncbi Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors
    T H C Cheung
    Psychopharmacology Section, Division of Psychiatry, University of Nottingham, Room B109, Medical School, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Psychopharmacology (Berl) 195:213-22. 2007
    ..It is not known whether this effect of d-amphetamine is mimicked by direct D(1)-like receptor stimulation...
  51. ncbi 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta
    Conrad Kunick
    Institut fur Pharmazeutische Chemie, Technische Universitat Braunschweig, Beethovenstrasse 55, 38106, Braunschweig, Germany
    Bioorg Med Chem Lett 14:413-6. 2004
    ..The charge distribution within the 1-azakenpaullone molecule is discussed as a possible explanation for the enhanced GSK-3beta selectivity of 1-azakenpaullone compared to other paullone derivatives...
  52. doi Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling
    Xinhua Zhang
    Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    J Neurosci 29:7766-75. 2009
    ..PI-linked D(1)-like receptor plays an important role in the regulation of astrocytic FGF-2 expression and neuroprotection which may provide a potential target for the drug discovery in Parkinson's disease...
  53. ncbi Dopamine modulates excitability of basolateral amygdala neurons in vitro
    Sven Kroner
    Center for Neural Basics Cognition, Deptartment of Neuroscience, University of Pittsburgh, Pittsburgh, Penssylvania
    J Neurophysiol 93:1598-610. 2005
    ....
  54. pmc Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: reversal by D(1) antagonists
    R Ciccocioppo
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 98:1976-81. 2001
    ..Moreover, the results implicate D(1)-dependent neural mechanisms within the medial prefrontal cortex and basolateral amygdala as substrates for cocaine-seeking behavior elicited by cocaine-predictive environmental stimuli...
  55. doi Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries
    Karl Fagerström
    Smokers Information Centre, Fagerstrom Consulting AB, Helsingborg, Sweden
    Curr Med Res Opin 26:2165-73. 2010
    ..A pooled analysis to evaluate the efficacy and safety of varenicline versus placebo for smoking cessation in Asian populations. A secondary objective was to compare the data to pooled trials among predominantly Western populations...
  56. doi The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system
    Mia Ericson
    Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
    J Pharmacol Exp Ther 329:225-30. 2009
    ....
  57. doi Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction
    Gerd Heusch
    Institut fur Pathophysiologie, Universitatsklinikum Essen, Essen, Germany
    Eur Heart J 29:2265-75. 2008
    ..Heart rate reduction by beta-blockade is associated with negative inotropism and unmasked alpha-adrenergic coronary vasoconstriction. Ivabradine is the only available bradycardic agent for clinical use...
  58. ncbi I f inhibition with ivabradine : electrophysiological effects and safety
    Irina Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London, UK
    Drug Saf 31:95-107. 2008
    ..The safety of ivabradine will be further assessed by postmarketing surveillance and during on-going clinical trials...
  59. pmc Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents
    G Heusch
    Institute for Pathophysiology, University of Essen Medical School, Essen, Germany
    Br J Pharmacol 153:1589-601. 2008
    ..Selective heart rate reduction, however, improves both flow and function without any residual negative effect such as unmasked alpha-adrenergic coronary vasoconstriction or negative inotropic action...
  60. doi Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 28:231-54. 2010
    ....
  61. ncbi Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor
    Frank J S Lee
    Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Toronto, M5T 1R8, Ontario, Canada
    Cell 111:219-30. 2002
    ..While one interaction is involved in the inhibition of NMDA receptor-gated currents, the other is implicated in the attenuation of NMDA receptor-mediated excitotoxicity through a PI-3 kinase-dependent pathway...
  62. doi Varenicline: a first-line treatment option for smoking cessation
    Gina Daubney Garrison
    Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York 12208 3492, USA
    Clin Ther 31:463-91. 2009
    ..This activity at the nicotine-receptor level may help patients achieve smoking cessation by reducing cravings/withdrawal symptoms and smoking satisfaction...
  63. ncbi Dopamine D1 receptors co-distribute with N-methyl-D-aspartic acid type-1 subunits and modulate synaptically-evoked N-methyl-D-aspartic acid currents in rat basolateral amygdala
    V M Pickel
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 411 East 69th Street, Room KB 410, New York, NY 10021, USA
    Neuroscience 142:671-90. 2006
    ....
  64. ncbi The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro
    Wolfgang F Schmid
    Institute of Inorganic Chemistry, Wahringerstr 42, A 1090 Vienna, Austria
    Inorg Chem 46:3645-56. 2007
    ..The novel complexes show an intercalative mode of interaction with DNA, which may render them attractive alternatives to metal compounds with a coordinative mode of interaction...
  65. doi Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
    William J Thomsen
    Arena Pharmaceuticals, Inc, 6166 Nancy Ridge Dr, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 325:577-87. 2008
    ..Upon discontinuation, body weight returned to control levels. These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity...
  66. ncbi Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors
    Kevin T Ball
    Department of Psychology and Program in Neural Science, Psychology Building, Indiana University, 1101 East 10th Street, Bloomington, IN 47405 7007, USA
    Brain Res 994:203-15. 2003
    ....
  67. pmc Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097
    Jianmei Wu
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Clin Cancer Res 18:2066-79. 2012
    ..This study investigated RO4929097 binding in plasma and its implications for the pharmacokinetics and pharmacodynamics of this compound...
  68. ncbi The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors
    M J Millan
    Institut de Recherches Servier, Psychopharmacology Department, Paris, France
    Psychopharmacology (Berl) 156:58-62. 2001
    ..57 nM. CONCLUSIONS: SCH23390 is a potent and high efficacy agonist at h5-HT2C receptors. Activation of 5-HT2C receptors by SCH23390 may contribute to its functional properties both in animals and in humans...
  69. ncbi 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: pharmacological manipulation
    Y Shirayama
    Division of Cortical Function Disorders, National Institute of Neuroscience, National Center of Neurology and Psychiatry NCNP, Tokyo, Kodaira, Japan
    Eur J Pharmacol 402:215-22. 2000
    ....
  70. ncbi Heart rate reduction during exercise-induced myocardial ischaemia and stunning
    Xavier Monnet
    Laboratoire de Pharmacologie, INSERM E 00 01, Faculte de Medecine Paris Sud, Paris, France
    Eur Heart J 25:579-86. 2004
    ..The effects of selective heart rate reduction by ivabradine (If inhibitor) were compared to those of atenolol on exercise-induced ischaemia and stunning...
  71. pmc Smoking outcome by psychiatric history after behavioral and varenicline treatment
    Jennifer B McClure
    Group Health Research Institute, Seattle, WA 98101, USA
    J Subst Abuse Treat 38:394-402. 2010
    ..Groups had similar 30-day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, p = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side effects...
  72. ncbi Direct and indirect actions of dopamine on the membrane potential in medium spiny neurons of the mouse neostriatum
    S Yasumoto
    Department of Physiology, Kurume University School of Medicine, Kurume 830 0011, Japan
    J Neurophysiol 87:1234-43. 2002
    ....
  73. ncbi Effects of the selective dopamine D(1) antagonists NNC 01-0112 and SCH 39166 on latent inhibition in the rat
    Karen M Trimble
    Department of Therapeutics and Pharmacology, Queen s University Belfast, Belfast BT7 1NN, Northern Ireland, UK
    Physiol Behav 77:115-23. 2002
    ..Since selective D(1) antagonists are not clinically effective, these results add further credibility for the relevance of LI as an animal model of psychosis...
  74. doi Acute hepatic injury associated with varenicline in a patient with underlying liver disease
    Andrew J Franck
    Department of Pharmacy, North Florida South Georgia Veterans Health System, Gainesville, FL 32608, USA
    Ann Pharmacother 43:1539-43. 2009
    ..To report a case of acute hepatic injury associated with varenicline...
  75. doi Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats
    Katharine A Brennan
    Institute of Environmental Science and Research Ltd, Porirua, New Zealand
    Behav Pharmacol 20:688-94. 2009
    ..The present results suggest that both D1-like and D2-like receptors contribute to the maintenance of MDMA self-administration, whereas MA self-administration was more sensitive to D1-like receptor blockade...
  76. doi 11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET
    Christophe Plisson
    GlaxoSmithKline, Clinical Imaging Centre, Hammersmith Hospital, London, United Kingdom
    J Nucl Med 50:2064-72. 2009
    ..The aim of this study was to synthesize and evaluate (11)C-labeled GSK189254 ((11)C-GSK189254) for imaging the histamine H(3) receptor in vivo by PET...
  77. doi Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease
    Jacqueline G O'Leary
    Division of Hepatology, Department of Medicine, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 15:1325-9. 2009
    ..Further study in a prospective clinical trial is needed to confirm safety and efficacy...
  78. pmc A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 13:820-6. 2011
    ..We have conducted a pilot study to obtain preliminary evidence of efficacy of varenicline for the treatment of ST users in Midwestern United States...
  79. pmc Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial
    John R Hughes
    Department of Psychiatry and Psychology, University of Vermont, Burlington, VT 05401, USA
    Nicotine Tob Res 13:955-64. 2011
    ..We tested whether varenicline, a partial nicotine agonist, would also increase future quit attempts...
  80. ncbi Anti-ischaemic effect of ivabradine
    Roberto Ferrari
    University of Ferrara, Italy
    Pharmacol Res 53:435-9. 2006
    ..We can expect distinct clinical benefits from long-term heart rate reduction in patients with chronic ischaemic disease...
  81. ncbi Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial
    Douglas E Jorenby
    University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
    JAMA 296:56-63. 2006
    ..Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine...
  82. doi Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL
    C Ceconi
    University of Ferrara, S Maugeri Foundation, Lumezzane, Italy
    Int J Cardiol 146:408-14. 2011
    ....
  83. doi Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis
    David Busseuil
    Research Center, Montreal Heart Institute, Universite de Montreal, Montreal, Quebec, Canada
    Cardiology 117:234-42. 2010
    ..To determine if heart rate (HR) reduction with ivabradine (IVA), a selective inhibitor of the pacemaker I(f) current, prevents cardiac dysfunction associated with dyslipidemia...
  84. doi Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, SE 416 85 Goteborg, Sweden
    Eur J Heart Fail 12:75-81. 2010
    ..The study will include approximately 6500 patients and will continue until > or =1600 primary endpoints have occurred. The first patient was randomized in October 2006, and the study is expected to end in 2010...
  85. pmc Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial
    H J Aubin
    Hôpital Emile Roux, Assistance Publique Hopitaux de Paris, Limeil Brevannes, Paris, France
    Thorax 63:717-24. 2008
    ..A study was undertaken to compare a 12-week standard regimen of varenicline with a 10-week standard regimen of transdermal nicotine replacement therapy (NRT) for smoking cessation...
  86. doi Dopamine D1 receptors and group I metabotropic glutamate receptors contribute to the induction of long-term potentiation in the nucleus accumbens
    Sietske M Schotanus
    Department of Physiology and Pharmacology, Section of Molecular Neurophysiology, The Karolinska Institute, Von Eulers Vag 8, 171 77 Stockholm, Sweden
    Neuropharmacology 54:837-44. 2008
    ..However, LTP is negatively regulated when endogenous levels of dopamine or glutamate are elevated...
  87. pmc Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice
    A Drouin
    Montreal Heart Institute, Research Center, Faculty of Medicine, Department of Surgery, Universite de Montreal, Montreal, Quebec, Canada
    Br J Pharmacol 154:749-57. 2008
    ..We tested the hypothesis that a reduction of resting heart rate with the cardiac pacemaker I(f) current inhibitor ivabradine prevents the endothelial dysfunction associated with dyslipidaemia...
  88. doi Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure
    Nadir Ulu
    Departments of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    J Cardiovasc Pharmacol 53:9-17. 2009
    ..In MI rats, HRR either by ivabradine or metoprolol treatment increases cardiac angiogenesis. Late HRR strategy was comparable to early HRR, suggesting that the beneficial effects are independent of the time of onset of therapy after MI...
  89. doi Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure
    Paul Milliez
    INSERM U942, Cardiovascular Research Center INSERM Lariboisière, Paris, France
    Am J Physiol Heart Circ Physiol 296:H435-41. 2009
    ..Such beneficial effects of Iva on cardiac remodeling open new clinical perspectives for the treatment of severe HF...
  90. doi Differential effects of heart rate reduction with ivabradine in two models of endothelial dysfunction and oxidative stress
    Swenja Kröller-Schön
    Department of Cardiology, Johannes Gutenberg University, 55101 Mainz, Germany
    Basic Res Cardiol 106:1147-58. 2011
    ..The absence of these protective ivabradine effects in angiotensin II-infused rats may relate to the treatment duration or the presence of arterial hypertension...
  91. ncbi SCH 23390: the first selective dopamine D1-like receptor antagonist
    J A Bourne
    Department of Physiology, Monash University, Clayton, Victoria, 3800, Australia
    CNS Drug Rev 7:399-414. 2001
    ..In summary, SCH 23390 has been a major tool in gaining a better understanding of the role of the dopamine system, more specifically the D1 receptor, in neurological function and dysfunction...
  92. doi Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:2357-72. 2010
    ..Given these factors, the benefit : risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit...
  93. pmc Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons
    Can Gao
    Department of Neuroscience, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois 60064 3095, USA
    J Neurochem 106:2489-501. 2008
    ..Our results show that tyrosine phosphorylation plays an important role in the trafficking of NR2B-containing NMDA receptors in PFC neurons and the regulation of their trafficking by DA receptors...
  94. pmc Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
    Abigail C Halperin
    University of Washington, Seattle, 1107 NE 45th Street, Suite 345, Seattle, WA 98105, USA
    J Subst Abuse Treat 36:428-34. 2009
    ..21%, p < .01). Counseling may improve tolerance of this medication and reduce the rate of discontinuation due to side effects...
  95. ncbi Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist
    Serena Tonstad
    Department of Preventive Cardiology, Ulleval University Hospital, Oslo, Norway
    J Cardiovasc Nurs 21:433-6. 2006
    ..Phase 3 studies have evaluated the effects of varenicline on inducing smoking cessation and maintaining smoking abstinence...
  96. doi Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition
    Hans Rollema
    Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    Biochem Pharmacol 78:813-24. 2009
    ....
  97. pmc Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice
    Danielle Gulick
    Department of Psychology, Neuroscience Program, Temple University, Weiss Hall, Rm 865, 1701 N 13th Street, Philadelphia, PA 19122, USA
    Neurobiol Learn Mem 90:230-6. 2008
    ..In addition, varenicline did not alter blood alcohol concentration. The smoking cessation aid varenicline may have therapeutic uses for treating ethanol-associated disruptions in cognitive processes...
  98. ncbi Distinct functions of the two isoforms of dopamine D2 receptors
    A Usiello
    Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS, INSERM, ULP, Illkirch, C U de Strasbourg, France
    Nature 408:199-203. 2000
    ..The absence of D2L reveals that D2S inhibits D1 receptor-mediated functions, uncovering a circuit of signalling interference between dopamine receptors...
  99. pmc Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues
    Niall P Hyland
    Centre for Neuroscience Research, King s College London, GKT School of Biomedical Sciences, Guy s Campus, London SE1 1UL, UK
    Br J Pharmacol 139:863-71. 2003
    ....
  100. ncbi Blockade of D1 dopaminergic transmission alleviates c-fos induction and cleaved caspase-3 expression in the brains of rat pups exposed to prenatal cocaine or perinatal asphyxia
    Ellen S Mitchell
    Department of Biomedical Sciences, State University at Albany, Albany, NY, USA
    Exp Neurol 182:64-74. 2003
    ..SCH 23390 decreased caspase-3 expression after both birth insults, indicating that the increased incidence of apoptosis is related to overactivation of dopaminergic pathways...
  101. ncbi Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers
    Masakazu Nakamura
    Department of Health Promotion and Education, Osaka Medical Center for Health Science and Promotion, Osaka, Japan
    Clin Ther 29:1040-56. 2007
    ..Varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, has been developed specifically for smoking cessation. In Japan, 39.3% of men smoke and this is a major public health concern...

Research Grants120 found, 100 shown here

  1. Synthesis of Bioactive Complex Alkaloids
    DAVID GIN; Fiscal Year: 2006
    ..pyrrolidines, as well as strain-accelerated [3,3]-sigmatropic rearrangement for the synthesis of complex benzazepines. Successful synthesis of these target molecules will not only lay the foundation for efficient and practical ..
  2. Evaluating Nicoting Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2007
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  3. High Dose Nicotine Patch Therapy for Spit Tobacco Users
    Jon Ebbert; Fiscal Year: 2004
    ..Our goal is to reduce the prevalence of ST use and decrease the incidence of oropharyngeal cancer through the development of effective treatment options for ST users. ..
  4. Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2009
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  5. Combination Therapy with Varenicline and Bupropion for Smoking Cessation
    Jon O Ebbert; Fiscal Year: 2010
    ..Combining medications together may increase the long-term smoking quit rates and decrease the death and disability associated with cigarette smoking. ..
  6. Brief Dental Office Intervention with Tobacco Quitline
    Jon Ebbert; Fiscal Year: 2005
    ..S. adult population smoking; and 3) 75% of smokers quitting for at least one day or longer because they are trying to quit. ..
  7. KIDNEY DISEASE RESEARCH TRAINING PROGRAM
    Vicente Torres; Fiscal Year: 2007
    ..abstract_text> ..
  8. REDOX, ACID/BASE, AND PATHOGENESIS OF ADPKD
    Vicente Torres; Fiscal Year: 2002
    ..The main thrust of the proposed studies is directed towards the identification of pathogenetic mechanisms than can be subject to preventive and therapeutic interventions. ..
  9. Novel treatments for polycystic kidney disease
    Vicente Torres; Fiscal Year: 2007
    ....
  10. Controlled Trial of Renin Angiotensin Blockade in ADPKD
    Vicente Torres; Fiscal Year: 2007
    ..Approximately one-half of these patients will have normal or near-normal renal function and one-half have mild to moderate renal insufficiency. The protocols for the Pilot Study will be conducted only at the Mayo Clinic. ..
  11. Polycystic Kidney Disease: Innovative Imaging to Assess Progression (PCC)
    Vicente Torres; Fiscal Year: 2007
    ....
  12. Novel treatment for polycystic kidney disease
    Vicente E Torres; Fiscal Year: 2010
    ....
  13. RENIN ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF ADPKD
    Vicente Torres; Fiscal Year: 1993
    ..The results of these studies will augment the understanding of the pathogenesis of cyst formation and hypertension in ADPKD and are likely to have a significant impact on the treatment of this disease...
  14. Novel treatments for polycystic kidney disease
    Vicente Torres; Fiscal Year: 2009
    ..abstract_text> ..
  15. CNS Mechanisms that Modulate Reward
    Kenneth D Carr; Fiscal Year: 2010
    ....
  16. OPIOID MECHANISMS THAT FACILITATE REWARD
    KENNETH CARR; Fiscal Year: 2006
    ..abstract_text> ..
  17. CNS Mechanisms that Modulate Reward
    KENNETH CARR; Fiscal Year: 2007
    ....
  18. AASK Cohort Study
    Kenneth Jamerson; Fiscal Year: 2007
    ..Ultimately, data from the AASK Cohort Study should enhance our understanding of the determine the progression of kidney disease. Such results might eventually lead to new ESRD. ..
  19. CNS OPIOID MECHANISMS THAT MODULATE REWARD AND AVERSION
    KENNETH CARR; Fiscal Year: 2002
    ....
  20. Step Up Wellness Program for Depression Physical Inactivity and Smoking
    JENNIFER MC CLURE; Fiscal Year: 2007
    ..This work will provide valuable information about the feasibility, acceptability, and impact of this comprehensive treatment approach and will lay the ground work for future research in this area. ..
  21. CHRONIC AND ACUTE TOLERANCE TO NICOTINE IN HUMANS
    Kenneth Perkins; Fiscal Year: 1999
    ....
  22. Optimizing an online motivational tobacco cessation program
    JENNIFER B MC CLURE; Fiscal Year: 2010
    ..Information learned from this study will advance the science of tailoring health risk communications, as well as inform how to best design an online motivational intervention for smoking cessation. ..
  23. Tobacco Smoking, Nicotine and Negative Affect Relief
    Kenneth Perkins; Fiscal Year: 2009
    ..In sum, this research will help address the fundamental question of why cigarette smoking is reinforcing. ..
  24. Tobacco Smoking, Nicotine and Negative Affect Relief
    Kenneth Perkins; Fiscal Year: 2007
    ..In sum, this research will help address the fundamental question of why cigarette smoking is reinforcing. ..
  25. CHRONIC AND ACUTE TOLERANCE TO NICOTINE IN HUMANS
    Kenneth Perkins; Fiscal Year: 1993
    ..Results may proivde directions for the study of mechanisms responsible for tolerance, as well as for investigations of physiological and behavioral aspects of nicotine depenence and smoking relapse...
  26. Affect, Context, and Placebo Responses to Nicotine
    Kenneth Perkins; Fiscal Year: 2005
    ..Secondary analyses may identify important individual characteristics associated with placebo responses, aiding in the prediction of which smokers ultimately are likely to benefit most from manipulation of placebo effects. ..
  27. DISCRIMINATIVE STIMULUS EFFECTS OF NICOTINE
    Kenneth Perkins; Fiscal Year: 2001
    ....
  28. Proactive Cessation Intervention with Biomarker Feedback
    JENNIFER MC CLURE; Fiscal Year: 2007
    ..If effective, this treatment strategy could have broad potential as a public health intervention. ..
  29. SEX DIFFERENCES IN NICOTINE REINFORCEMENT: HUMAN/ANIMAL
    Kenneth Perkins; Fiscal Year: 2003
    ....
  30. INDIVIDUAL VARIATION IN NICOTINE SENSITIVITY IN HUMANS
    Kenneth Perkins; Fiscal Year: 2003
    ..e., in nicotine-naive individuals). Results will provide directions for future research on vulnerability to tobacco dependence and for targeted efforts to prevent smoking onset. ..
  31. ASK, ADVISE, REFER: Promoting Pharmacy-based Referrals to Tobacco Quitlines
    Karen Hudmon; Fiscal Year: 2009
    ....
  32. SAFETY OF A NICOTINE REDUCTION STRATEGY
    Neal Benowitz; Fiscal Year: 2002
    ..The proposed research is needed to guide the FDA as how best to regulate nicotine in cigarettes and is an essential first step in examining the feasibility of a national nicotine regulation program. ..
  33. Safety of Nicotine Reduction Strategy
    Neal Benowitz; Fiscal Year: 2009
    ..The proposed research is needed to guide governmental regulators as to how best to regulate nicotine in cigarettes and is an essential first step in examining the feasibility of a national regulation program. ..